Drug Trial Radar · NCT06005597
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
407
Actual
Start
Mar 1, 2024
Primary completion
Sep 25, 2024
Study completion Oct 16, 2024
Sponsor
- Lead sponsor
- NewAmsterdam PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to evaluate the efficacy, safety and tolerability of obicetrapib 10mg and ezetimibe 10mg fixed dose combination as an adjunct to diet and maximally tolerated lipid-lowering therapy.
Conditions
- Dyslipidemias
- Hypercholesterolemia
- Familial Hypercholesterolemia
- ASCVD
- High Cholesterol
Interventions
Combination TherapyCombination product
tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination
Monotherapy obicetrapibDrug
tablet; 10mg obicetrapib
Monotherapy ezetimibeDrug
capsule; 10mg ezetimibe
Combination Therapy placeboOther
tablet; no active ingredient
Obicetrapib PlaceboOther
tablet; no active ingredient
Ezetimibe PlaceboOther
capsule; no active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-CTime frame: 84 Days
- Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-CTime frame: 84 Days
- Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-CTime frame: 84 Days
- Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-CTime frame: 84 Days
Locations
45 sites in 1 country. Site status is shown where the registry gives one.
East Valley Diabetes & Endocrinology
Gilbert, Arizona
Jacksonville Center for Clinical Research
Jacksonville, Florida
Progressive Medical Research
Port Orange, Florida
Centricity Research - Columbus
Columbus, Georgia
Center for Advanced Research and Education
Gainesville, Georgia
NSC Research
Johns Creek, Georgia
North Georgia Clinical Research
Woodstock, Georgia
Evanston Premier Healthcare Research LLC
Skokie, Illinois
Cardiovascular Research of Northwest Indiana, LLC
Munster, Indiana
Grace Research, LLC - Bossier City, LA
Bossier City, Louisiana
Horizon Research Group of Opelousas
Eunice, Louisiana
Maryland Cardiovascular Specialists
Baltimore, Maryland
TidalHealth Peninsula Regional, Inc.
Salisbury, Maryland
McClaren Bay Heart and Vascular
Bay City, Michigan
Northern Pines Health Center
Buckley, Michigan
Sparrow Clinical Research Institute
Lansing, Michigan
Oakland Medical Research Center
Troy, Michigan
CentraCare Heart & Vascular Center
Saint Cloud, Minnesota
North Mississippi Medical Center
Tupelo, Mississippi
St. Louis Heart and Vascular Cardiology
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Triad Internal Medicine
Asheboro, North Carolina
Cary Research Group, LLC
Cary, North Carolina
Novant Health Clinical Research, LLC
Charlotte, North Carolina
Novant Health Heart and Vascular Institute
Charlotte, North Carolina
Lucas Research, Inc
Morehead City, North Carolina
Wilmington Health Associates
Wilmington, North Carolina
Metabolic and Atherosclerosis Research Center
Cincinnati, Ohio
Summit Research Group, LLC
Stow, Ohio
Capital Area Research
Camp Hill, Pennsylvania
Monument Health Clinical Research, a department of Monument Health Rapid City Hospital, Inc
Rapid City, South Dakota
Chattanooga Research & Medicine, PLLC
Chattanooga, Tennessee
Cardiovascular Research of Knoxville
Powell, Tennessee
PharmaTex Research, LLC
Amarillo, Texas
Amarillo Heart Clinical Research Institute, Inc
Amarillo, Texas
South Texas Clinical Research
Corpus Christi, Texas
Diabetes and Thyroid Center of Fort Worth
Fort Worth, Texas
Baylor College of Medicine
Houston, Texas
Juno Research, LLC - Medical Center Office
Houston, Texas
DM Clinical Research
Houston, Texas
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.